FDA approves first treatment for COVID-19
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation
- Details
- Category: EMA
![EMA EMA](/images/logo/ema.png)
FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
FDA revokes emergency use authorization for chloroquine and hydroxychloroquine
- Details
- Category: FDA
![FDA FDA](/images/logo/fda.png)
Global regulators commit to cooperate on observational research in the context of COVID-19
- Details
- Category: EMA
![EMA EMA](/images/logo/ema.png)
More Pharma News ...
- FDA takes new actions to accelerate development of novel prevention, treatment options for COVID-19
- FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
- FDA reiterates importance of close patient supervision for 'off-label' use of antimalarial drugs
- FDA encourages recovered patients to donate plasma for development of blood-related therapies
- FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19
- FDA Continues to Accelerate Development of Novel Therapies for COVID-19
- The FDA is facilitating access to convalescent plasma collected from recovered COVID-19 patients